Mark Genesen, MD
Gynecologic Oncology · Rancho Mirage, CANPI 1043250566
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for gynecologic oncology clinicians in CA, where the typical reported total is $1,602.
Across 10 payments — averaging $75.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galvanize Therapeutics, Inc$136
- AstraZeneca$125
- Medical Device Business Services, Inc.$124
- Seagen Inc.$121
- Eisai Inc.$100
- Intuitive Surgical$82
- plus $65 from 2 others
Across 7 payments — averaging $12,402 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$87K
What the payments were for
- Food & beverage$753100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galvanize Therapeutics, Inc | 1 | $136 |
| AstraZeneca | 2 | $125 |
| Medical Device Business Services, Inc. | 1 | $124 |
| Seagen Inc. | 1 | $121 |
| Eisai Inc. | 1 | $100 |
| Intuitive Surgical | 1 | $82 |
| AbbVie | 2 | $41 |
| Pfizer | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$136
- ETHICON$124
- TIVDAK$121
- LYNPARZA$118
- LENVIMA$100
How this compares
$753 in reported general payments places this provider in the 40th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 14 | $909 |
| Estradiol | 14 | $820 |
| Celecoxib | 49 | $522 |
| Gabapentin | 46 | $235 |
| Ondansetron OdtOndansetron | 12 | $163 |
| Tramadol Hcl | 67 | $122 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Rancho Mirage
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
- Oliver DorigoStanford$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.